In conclusion, inhibition of CBP/β-catenin increased the anti-tumor effects of anti-PD-L1 Ab therapy against metastatic liver tumors derived from colon cancer by promoting the accumulation of CD8+ T-cells and inducing a shift in the properties of macrophages toward a cytotoxic phenotype. The gene discussed is CREBBP; the disease is malignant colon neoplasm.